Adhering to the service tenet of "Integrity, Innovation, Harmony, and Win-win", We have established a complete one-stop procurement and comprehensive solution service system.
Selpercatinib Inhibitor LOXO-292 cas 2152628-33-4 is an oral and selective investigational new agent that is being evaluated for the treatment of patients with cancers that harbor alterations in the RET kinase in the LIBRETTO-001 trial (NCT03157128).
Product introduction：
CAS: 2152628-33-4
MF: C29H31N7O3
Molecular Weight: 525.6
Synoyms: LOXO292, Selpercatinib, LY3527723, CPD2206
Description: Selpercatinib Inhibitor LOXO-292 cas 2152628-33-4 is an oral and selective investigational new agent that is being evaluated for the treatment of patients with cancers that harbor alterations in the RET kinase in the LIBRETTO-001 trial (NCT03157128).
Application: Treat advanced tumors, histiocytic disorders that have activating RET gene alterations. Selpercatinib block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.
Other chemical names: SELPERCATINIB, Selpercatinib(LOXO-292)
Certificate of analysis
|
TETS |
STANDARD |
RESULTS |
|
Appearance |
White to off-white powder |
White powder |
|
LC/MS |
Conformity with the structure |
Conform |
|
NMR |
Conformity with the structure |
Conform |
|
Loss on drying |
≤0.5% |
0.21% |
|
Related substances by HPLC |
Single impurity≤ 0.5% Total impurities≤1.0% |
0.3% 0.42% |
|
Assay |
Calculated on anhydrous basis, 98.0%~102.0% |
99.3% |
Sign up for our latest news & articles. We won’t give you spam mails.
Note: We do not publish your email
